Scientific Programme

Thursday 09 Nov

12:30

Welcome

Session: From basic science to clinical application

Chair: Jan B. Vermorken (BE)

13:00

Oral potentially malignant disorders (OPMD): an update

Ruud Brakenhoff (NL)

13:25

The role of artificial intelligence in OPMD

Pierre Saintigny (F)

13:50

Treatment of OPMD and first results of immune checkpoint inhibitors

Paolo Bossi (I)

14:15

Innovations in cell-based assays for drug discovery and drug evaluation

Ingeborg Tinhofer (DE)

14:40

Break and poster viewing

15:10

Is the ESCAT ranking of support in head and neck cancer management?

Maud Kamal (F)

15:35

Mechanism of action and potential use of SMAC mimetics in HNSCC

Ben O’Leary (UK)

16:00

Precision medicine beyond genomics

Enrique Sanz (CA)

16:25

Proffered paper session 1

chaired by René Leemans (NL)

17:30

Clinical cases: Panel discussion

chaired by Brian O’Sullivan (CA)

Panel: René Leemans, Piero Nicolai, Maria Isabel Falguera Uceda, Hans Langendijk, Jorge Contreras, Jean-Pascal Machiels, Antonio Rueda, Marc Oliva, Almudena Pérez Lara, Paolo Bossi

19:00

Welcome reception

Friday 10 Nov

Session Primary disease (1)

Chair Hans Langendijk (NL)

08:30

Sentinel Node Biopsy in cN0 Early-Stage Oral Cavity Cancer: what is the evidence?

Clare Schilling (UK)

08:55

Partial laryngeal surgery in 2023

Giovanni Succo (I)

09:20

Managing the internal carotid artery in head and neck cancer: where are we?

Piero Nicolai (I)

09:45

Improving quality of reconstructive surgery in head and neck cancer

Sat Parmar (UK)

10:10

Coffee break and poster viewing

10:45

Innovation in radiotherapy: “FLASH-therapy”

Jean Bourhis (CH)

11:10

Hypoxia in head and neck cancer: current relevance

Olivier Feron (BE)

11:35

Hyperthermia: a game changer in the management of head and neck cancer?

Anthony Kong (UK)

12:00

Clinical cases: Panel discussion

chaired by Piero Nicolai (I)

Panel: René Leemans, Carlos Chiesa, Maria Isabel Falguera Uceda, Jean-Pascal Machiels, Antonio Rueda, Marc Oliva, Kevin Harrington, Jorge Contreras, Almudena Pérez Lara, Petr Szturz

13:30

Lunch and poster viewing

Session Primary disease (2)

Chair: Piero Nicolai (I)

14:30

Prognostic factors in HPV-positive oropharyngeal cancer: an update

Brian O’Sullivan (CA)

14:55

Immunotherapy and novel agents in locoregionally advanced HNSCC

Jean-Pascal Machiels (BE)

15:20

Is reducing the extent of local treatments justified after successful neoadjuvant therapy?

Andreas Dietz (DE)

15:45

Noninvasive biomarkers predicting outcome in patients with locoregionally advanced HNSCC

Ricard Mesia (ES)

16:10

Coffee break

16:40

Innovations in head and neck surgery in the 21st century

René Leemans (NL)

17:05

Impact of emerging technology developments in proton therapy

Hans Langendijk (NL)

17:30

Proffered paper session

chaired by Jean-Pascal Machiels (BE)

18:30

Debate

moderator Jan Vermorken (BE)

This house believes that hypoxic modification should be used to enhance the effect of
(chemo)radiation in patients with locoregionally advanced HNSCC
Pro-position: Jens Overgaard (seconded by Jean Bourhis (CH))
Contra-position: Vincent Gregoire (seconded by Hans Langendijk (NL))

Saturday 11 Nov

Session Recurrent/Metastatic (R/M) disease

Chair: Brian O’Sullivan (CA)

08:30

50 years of systemic therapy: what have we gained?

Jan Vermorken (BE)

08:55

The potential roles of Antibody-Drug Conjugates in head and neck cancer

Christophe Le Tourneau (F)

09:20

Intratumoral drug administration: more potential in head and neck cancer?

Kevin Harrington (UK)